OC 4
Alternative Names: OC-4Latest Information Update: 08 Feb 2023
At a glance
- Originator OneChain Immunotherapeutics
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Glioblastoma
Most Recent Events
- 28 Dec 2022 Early research in Glioblastoma in Spain (Parenteral) (OneChain Immunotherapeutics pipeline, December 2022)